Transforming Healthcare Through Patient Engagement

Published Nov 13, 2018
Barcelona, Spain—13 November 2018—ISPOR, the professional society for health economics and outcomes research, held a spotlight session this afternoon at ISPOR Europe 2018, “Transforming Healthcare: The Impact of Patient Engagement” [IP15]. Speakers included:
  • Moderator: Nancy Devlin, PhD, Office of Health Economics, London, England, UK
  • Jan Geissler, MBA, EUPATI, Munich, Germany
  • Suzanne Schrandt, JD, Arthritis Foundation, Atlanta, GA, USA
  • Nicola Bedlington, BA Hons, European Patients Forum, Brussels, Belgium
The patient engagement movement has led to more systematic involvement of patients and patient representatives in Europe and the United States over the past decade. This initiative has brought the “patient voice” into treatment choices, research and development decisions, clinical trial and outcomes research design, and regulatory and reimbursement decision making. This panel examined the impact patient engagement has had on health outcomes and on creating more patient-centered healthcare systems. In this session, panelists outlined the history of the patient movement and the global emergence of patient engagement. The patient movement has influenced the European Union’s (EU) perspective on health policy and is still transforming the EU regulatory system. In the United States, patients are engaging in healthcare research, resulting in many improvements in health outcomes and healthcare overall. In closing, the panel discussed how future healthcare will be further transformed due to the efforts of the patient movement. ISPOR is recognized globally as the leading professional society in HEOR and its role in improving healthcare decisions. ISPOR Europe 2018 is the leading HEOR conference in Europe and draws more than 5000 healthcare stakeholders, including researchers and academicians, assessors and regulators, payers and policy makers, the life sciences industry, and patient engagement organizations. Additional information on ISPOR Europe 2018 can be found here. Released presentations from the conference can be found here. Interested parties can follow news and developments from the conference on social media using the hashtag #ISPORBarcelona.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE®-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: www.twitter.com/ISPORorg (@ISPORorg) | YouTube: www.youtube.com/user/ISPORorg/videos | Facebook: www.facebook.com/ISPORorg | Instagram: www.instagram.com/ISPORorg

Related Stories

New Research Collection Reveals How Artificial Intelligence Is Reshaping Health Economics

Nov 6, 2025

The PhRMA Foundation and ISPOR announced the publication of a special themed section of research papers that explores the dynamic intersection of artificial intelligence (AI) and health economics and outcomes research (HEOR).

ISPOR Announces 2025 Health Economics and Outcomes Research Award Honorees

Oct 20, 2025

ISPOR announced the recipients of its 2025 Health Economics and Outcomes Research (HEOR) Scientific and Leadership Awards. ISPOR Scientific Awards are designed to foster and recognize excellence and outstanding achievement in HEOR and its Leadership Awards recognize excellence and outstanding leadership in the field.

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×